Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Gain Therapeutics (NASDAQ:GANX) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock.

A number of other research firms have also recently weighed in on GANX. Roth Capital lowered their price objective on shares of Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 13th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research report on Wednesday, October 8th. BTIG Research restated a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Monday, September 8th. Finally, Maxim Group increased their price objective on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.86.

Gain Therapeutics Stock Performance

NASDAQ:GANX opened at $1.90 on Monday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.79 and a current ratio of 1.79. The stock has a market capitalization of $68.31 million, a P/E ratio of -3.02 and a beta of 0.11. The company has a 50 day moving average price of $1.77 and a 200 day moving average price of $1.78. Gain Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $3.19.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). Equities research analysts forecast that Gain Therapeutics will post -1 EPS for the current year.

Institutional Investors Weigh In On Gain Therapeutics

Several institutional investors have recently modified their holdings of GANX. Dauntless Investment Group LLC purchased a new stake in shares of Gain Therapeutics during the 1st quarter worth $240,000. Marshall Wace LLP lifted its position in shares of Gain Therapeutics by 41.0% during the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock worth $498,000 after purchasing an additional 80,407 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new stake in shares of Gain Therapeutics during the 1st quarter worth $91,000. Finally, Geode Capital Management LLC lifted its position in shares of Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock worth $523,000 after purchasing an additional 8,251 shares during the last quarter. 11.97% of the stock is owned by hedge funds and other institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.